Cayston Review To Focus On Missing Data, Additional Dosing Regimens
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee will wrestle with missing data and whether Gilead's cystic fibrosis drug, Cayston, needs additional studies for new dosing regimens.
You may also be interested in...
Gilead's Cayston Picks Up Panel Endorsement, But Not Based On Data
It was the orphan setting and urgent need for new therapies to treat the respiratory and pulmonary symptoms of cystic fibrosis that led FDA's Anti-Infective Drugs Advisory Committee to support approval of Gilead's Cayston (aztreonam lysine)
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.